These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12458127)

  • 1. Antimicrobial activity of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), compared to other quinolones, against clinical isolates from cancer patients.
    Rolston KV; Frisbee-Hume S; LeBlanc BM; Streeter H; Ho DH
    Diagn Microbiol Infect Dis; 2002 Oct; 44(2):187-94. PubMed ID: 12458127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro antimicrobial activity of moxifloxacin compared to other quinolones against recent clinical bacterial isolates from hospitalized and community-based cancer patients.
    Rolston KV; Frisbee-Hume S; LeBlanc B; Streeter H; Ho DH
    Diagn Microbiol Infect Dis; 2003 Oct; 47(2):441-9. PubMed ID: 14522520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T
    J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative in vitro activity of garenoxacin (BMS-284756). Sentry program, Spain (1999-2000)].
    Loza E; Cantón R; Pascual A; Tubau F; Morosini MI; Almaraz F; Perea E; Martín R; Jones RN; Baquero F
    Enferm Infecc Microbiol Clin; 2003 Oct; 21(8):404-9. PubMed ID: 14525705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.
    Fung-Tomc JC; Minassian B; Kolek B; Huczko E; Aleksunes L; Stickle T; Washo T; Gradelski E; Valera L; Bonner DP
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3351-6. PubMed ID: 11083639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients.
    Rolston KV; Vaziri I; Frisbee-Hume S; Streeter H; LeBlanc B
    Chemotherapy; 2004 Nov; 50(5):214-20. PubMed ID: 15523180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000).
    Kirby JT; Mutnick AH; Jones RN; Biedenbach DJ; Pfaller MA
    Diagn Microbiol Infect Dis; 2002 Aug; 43(4):303-9. PubMed ID: 12151191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lomefloxacin, a new difluoroquinolone: in vitro activity against gram-positive and gram-negative bacteria.
    Hoban D; Grabowski M; Koss J; Weselowski V
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):77S-82S. PubMed ID: 2791502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of PD 117 596, a new quinolone, against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Ho DH; Bodey GP
    J Antimicrob Chemother; 1990 Jul; 26(1):39-44. PubMed ID: 2211445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the bactericidal activities and post-antibiotic effects of the Des-F(6)-quinolone BMS-284756, levofloxacin, and ciprofloxacin against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
    Ryan BM; Mazzucco CE; Lawrence LE; Ho H; Warr G; Barrett JF; Frosco M
    Eur J Clin Microbiol Infect Dis; 2002 Jan; 21(1):27-34. PubMed ID: 11913498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Arpi M; Gahrn-Hansen B; Søgaard P; Bentzon MW
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
    Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
    Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
    Blondeau JM; Laskowski R; Bjarnason J; Stewart C
    Int J Antimicrob Agents; 2000 Feb; 14(1):45-50. PubMed ID: 10717500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative killing kinetics of the novel des-fluoro(6) quinolone BMS-284756, fluoroquinolones, vancomycin and beta-lactams.
    Gradelski E; Valera L; Kolek B; Bonner D; Fung-Tomc J
    Int J Antimicrob Agents; 2001 Jul; 18(1):43-8. PubMed ID: 11463525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
    Seifert H
    Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.